STARTRK-2
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

STARTRK-2

Sponsor: Ignyta, Inc.

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.